Great Lakes Advisors’s United Therapeutics UTHR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.01M Sell
7,399
-7,019
-49% -$3.95M 0.03% 282
2026
Q1
$8.55M Buy
14,418
+7,228
+101% +$3.6M 0.07% 163
2025
Q4
$3.5M Buy
7,190
+2,687
+60% +$1.25M 0.03% 308
2025
Q3
$1.89M Buy
4,503
+2,975
+195% +$1M 0.02% 441
2025
Q2
$439K Sell
1,528
-964
-39% -$288K ﹤0.01% 636
2025
Q1
$768K Buy
2,492
+518
+26% +$178K 0.01% 543
2024
Q4
$697K Buy
1,974
+31
+2% +$11.4K 0.01% 617
2024
Q3
$696K Buy
1,943
+169
+10% +$57.1K 0.01% 614
2024
Q2
$565K Buy
1,774
+329
+23% +$87.1K 0.01% 638
2024
Q1
$332K Sell
1,445
-693
-32% -$156K ﹤0.01% 672
2023
Q4
$470K Buy
2,138
+1,105
+107% +$255K ﹤0.01% 617
2023
Q3
$233K Buy
+1,033
New +$238K ﹤0.01% 699
2020
Q1
Sell
-3,486
Closed -$307K 591
2019
Q4
$307K Buy
+3,486
New +$307K 0.01% 494
2019
Q1
Sell
-57,608
Closed -$6.27M 607
2018
Q4
$6.27M Buy
57,608
+28,652
+99% +$3.32M 0.15% 163
2018
Q3
$3.7M Buy
+28,956
New +$3.58M 0.08% 239
2014
Q4
Sell
-17,299
Closed -$2.23M 552
2014
Q3
$2.23M Buy
+17,299
New +$1.78M 0.07% 182

Other funds holding UTHR

Great Lakes Advisors's UTHR Position: Q2 2026 in Review

Great Lakes Advisors reduced its United Therapeutics (UTHR) stake by 49% in Q2 2026, selling an estimated $3.95M and leaving 7,399 shares worth $4.01M. The position accounts for 0.03% of the portfolio, ranked #282.

Great Lakes Advisors first reported a position in UTHR in Q3 2014 and has held it in 16 quarters since. The position peaked at $8.55M in Q1 2026. 875 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Great Lakes Advisors held 7,399 shares of United Therapeutics worth $4.01M as of Q2 2026.
  • Great Lakes Advisors sold 7,019 United Therapeutics shares in Q2 2026, an estimated $3.95M.
  • United Therapeutics made up 0.03% of Great Lakes Advisors's portfolio in Q2 2026, its #282 holding.
  • Great Lakes Advisors first reported a position in United Therapeutics in Q3 2014 and has held it in 16 quarters since.
  • Great Lakes Advisors's United Therapeutics position peaked at $8.55M in Q1 2026.
  • 875 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Great Lakes Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.